Full-Time
Pharmacy Sales Representative
Viatris
10,001+ employees
Global pharma selling generics and biosimilars
No salary listed
Brisbane QLD, Australia + 2 more
More locations: Takura, Australia | Maroochydore QLD, Australia
In Person
 Sales & Account Management (1) |
|---|
- Bachelor’s degree or equivalent in Pharmacy, Science or Sales
- At least 1 years experience working within Australia’s generic market
- 1-2 years’ experience in B2B complex sales environments
- Proven track record of success in exceeding sales targets
- Excellent communication skills (written and verbal)
- Must be eligible to work in Australia (Australian Citizen or appropriate Visa holder)
- Maintain the designated territory ensuring continuation of optimum service to 1st line accounts
- Exceeding net sales target of dispensary and OTC pharmacy products within a defined territory of supporting customers and acquisition targets
- Maintain loyalty of 1st line accounts through building close relationships to ensure their requirements are being met by the company’s products where possible
- Execute agreed business tactics to optimize substitution opportunities
- Design & execute quarterly business plans which include targets, action plan & outcomes for each account
- Facilitate a 1st class sales experience using business insights, analytics & innovative deal-level strategies
- Acknowledge & overcome customer concerns. Take ownership of territory issues & provide appropriate solutions. Escalate to Regional Business Manager if required
- Consistently record & assess call outcomes in call notes within the required system
Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.
Company Size
10,001+
Company Stage
IPO
Headquarters
Canonsburg, Pennsylvania
Founded
1961
Simplify's Take
What believers are saying
- Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
- Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
- UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.
What critics are saying
- FDA Indore warning letter slashes stock 15% on February 27, 2025.
- Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
- FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.
What makes Viatris unique
- Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
- Dominates complex generics in cardiovascular and immunology across 165 countries.
- Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Paid Holidays
Company News
Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.
Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.
Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.
Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.
Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.